MA28391B1 - Dérivés de 3-cycloalkylaminopyrrolidine utiles comme modulateurs de récepteurs de chimiokines - Google Patents

Dérivés de 3-cycloalkylaminopyrrolidine utiles comme modulateurs de récepteurs de chimiokines

Info

Publication number
MA28391B1
MA28391B1 MA29111A MA29111A MA28391B1 MA 28391 B1 MA28391 B1 MA 28391B1 MA 29111 A MA29111 A MA 29111A MA 29111 A MA29111 A MA 29111A MA 28391 B1 MA28391 B1 MA 28391B1
Authority
MA
Morocco
Prior art keywords
chemokine receptor
receptor modulators
derivatives useful
cycloalkylaminopyrrolidine derivatives
cycloalkylaminopyrrolidine
Prior art date
Application number
MA29111A
Other languages
English (en)
Inventor
Chu-Biao Xue
Brian Metcalf
Amy Qi Han
Darius J Robinson
Changsheng Zheng
Anlai Wang
Yingxin Zhang
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of MA28391B1 publication Critical patent/MA28391B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
MA29111A 2003-12-18 2006-06-16 Dérivés de 3-cycloalkylaminopyrrolidine utiles comme modulateurs de récepteurs de chimiokines MA28391B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53127003P 2003-12-18 2003-12-18

Publications (1)

Publication Number Publication Date
MA28391B1 true MA28391B1 (fr) 2007-01-02

Family

ID=34710216

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29111A MA28391B1 (fr) 2003-12-18 2006-06-16 Dérivés de 3-cycloalkylaminopyrrolidine utiles comme modulateurs de récepteurs de chimiokines

Country Status (27)

Country Link
US (5) US7576089B2 (fr)
EP (1) EP1696919B1 (fr)
JP (1) JP4740151B2 (fr)
KR (2) KR20080052683A (fr)
CN (2) CN1893945A (fr)
AP (1) AP2439A (fr)
AU (1) AU2004305079B2 (fr)
BR (1) BRPI0417605B8 (fr)
CA (1) CA2550596C (fr)
CR (1) CR8455A (fr)
DK (1) DK1696919T3 (fr)
EA (1) EA013631B1 (fr)
EC (1) ECSP066615A (fr)
ES (1) ES2439894T3 (fr)
GE (1) GEP20084505B (fr)
IL (1) IL175953A (fr)
IS (1) IS2956B (fr)
MA (1) MA28391B1 (fr)
MX (1) MXPA06007000A (fr)
NI (1) NI200600136A (fr)
NO (1) NO336486B1 (fr)
NZ (1) NZ547316A (fr)
OA (1) OA13338A (fr)
TN (1) TNSN06188A1 (fr)
UA (1) UA82917C2 (fr)
WO (1) WO2005060665A2 (fr)
ZA (1) ZA200604875B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL376925A1 (pl) * 2002-11-27 2006-01-09 Incyte Corporation Pochodne 3-aminopirolidyny jako modulatory receptorów chemokiny
AU2005234596B8 (en) * 2004-04-13 2011-06-16 Incyte Holdings Corporation Piperazinylpiperidine derivatives as chemokine receptor antagonists
JP2007537264A (ja) 2004-05-11 2007-12-20 インサイト コーポレイション ケモカインレセプタのモジュレータとしての３−（４−ヘテロアリールシクロヘキシルアミノ）シクロペンタンカルボキサミド
EP1763347A4 (fr) 2004-06-28 2009-05-20 Incyte Corp 3-aminocyclopentanecarboxamides utilises en tant que modulateurs des recepteurs des chimiokines
GEP20094843B (en) 2004-06-28 2009-11-25 Incyte Corp 3-aminocyclopentane carboxamides as modulators of chemokine receptors
WO2006013427A2 (fr) * 2004-07-30 2006-02-09 Pfizer Products Inc. Methodes de traitement de maladies ou de troubles induits par ccr2
US20080187508A1 (en) * 2004-09-08 2008-08-07 Boys Town National Research Hospital Treatment of Golmerular Basement Membrane Disease Involving Matrix Metalloproteinase-12
MX2007003332A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
JP4958786B2 (ja) * 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
MX2007003327A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
EP2289510A1 (fr) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Dérivés hétérocycliques pour le traitement des maladies induites par des enzymes stearoyl-coa desaturase
MX2007003319A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
EP2269610A3 (fr) 2004-09-20 2011-03-09 Xenon Pharmaceuticals Inc. Dérivés hétérocycliques et leur utilisation en tant qu'inhibiteurs de la stearoyl-coa desaturase
EP1799667B1 (fr) 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation comme agents therapeutiques
US8937184B2 (en) * 2005-02-16 2015-01-20 Abbvie B.V. 1H-imidazole derivatives as cannabinoid CB2 receptor modulators
BRPI0611187A2 (pt) 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
WO2007053499A2 (fr) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Composés pouvant être employés en tant qu'antagonistes de ccr2
US8067457B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
US7910108B2 (en) 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
CL2007002958A1 (es) * 2006-10-12 2008-05-09 Epix Delaware Inc Compuestos derivados de heteroaril-carboxamida, antagonistas del receptor de quimioquina; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades tales como rechazo de transplante de organos, artritis reumatoidea, lupus, entr
CN101534824A (zh) 2006-11-17 2009-09-16 艾博特公司 作为化学活素受体拮抗剂的氨基吡咯烷
AR065369A1 (es) * 2007-02-19 2009-06-03 Novartis Ag Derivados de ciclohexil - amida del acido aril- carboxilico
WO2008145681A2 (fr) * 2007-05-31 2008-12-04 Boehringer Ingelheim International Gmbh Antagonistes des récepteurs ccr2 et utilisations de ceux-ci
US7977358B2 (en) * 2007-07-26 2011-07-12 Hoffmann-La Roche Inc. Pyrazol derivatives
MX2010003113A (es) * 2007-09-25 2010-04-01 Abbott Lab Compuestos de octahidropentaleno como antagonistas del receptor de quimiocina.
AU2009259496A1 (en) * 2008-06-18 2009-12-23 F. Hoffmann-La Roche Ag Novel heteroaryl carboxamide derivatives
WO2010003240A1 (fr) 2008-07-08 2010-01-14 The Royal Institution For The Advancement Of Learning/Mcgill University Conjugués de gm-csf et de ccl2 tronqué, leurs procédés et applications
CA2743030C (fr) 2008-11-26 2013-10-22 Pfizer Inc. 3-aminocyclopentanecarboxamides en tant que modulateurs des recepteurs de chimiokines
CA2745969C (fr) 2008-12-10 2017-04-25 Janssen Pharmaceutica Nv Antagonistes de ccr2 a base de 4-azetidinyl-1-heteroaryl-cyclohexanol
DK2379525T3 (en) 2008-12-19 2015-10-19 Boehringer Ingelheim Int Cyclic pyrimidin-4-carboxamides, as CCR2 receptor antagonists for the treatment of inflammation, asthma and COPD
NZ595432A (en) 2009-04-17 2013-12-20 Janssen Pharmaceutica Nv 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2
KR101151415B1 (ko) * 2009-07-10 2012-06-01 양지화학 주식회사 Ｃｃｒ２ 길항제로서의 피페라지닐에틸 3-아미노피롤리딘 유도체
WO2011073154A1 (fr) 2009-12-17 2011-06-23 Boehringer Ingelheim International Gmbh Nouveaux antagonistes du récepteur ccr2 et leurs utilisations
EP2569295B1 (fr) 2010-05-12 2014-11-19 Boehringer Ingelheim International GmbH Nouveaux antagonistes du récepteur ccr2, son procédé de production et utilisation associée en tant que médicaments
US8877745B2 (en) 2010-05-12 2014-11-04 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8841313B2 (en) 2010-05-17 2014-09-23 Boehringer Ingelheim International Gmbh CCR2 antagonists and uses thereof
US9018212B2 (en) 2010-05-25 2015-04-28 Boehringer Ingelheim International Gmbh Pyridazine carboxamides as CCR2 receptor antagonists
EP2576538B1 (fr) 2010-06-01 2015-10-28 Boehringer Ingelheim International GmbH Nouveaux antagonistes de CCR2
WO2011159854A1 (fr) 2010-06-17 2011-12-22 Janssen Pharmaceutica Nv Antagonistes du ccr2 à base de cyclohexyl-azétidinyle
BR112013000925A2 (pt) 2010-07-15 2020-12-01 Bayer Intellectual Property Gmbh compostos heterocíclicos como pesticidas
WO2012075115A1 (fr) 2010-12-01 2012-06-07 Janssen Pharmaceutica Nv Antagonistes de ccr2 consistant en des cyclohexylamino-4-pipéridinyl-acétamides substitués en position 4
WO2012114223A1 (fr) * 2011-02-25 2012-08-30 Pfizer Limited Méthode de traitement de la fibrose hépatique
JP5786258B2 (ja) 2011-07-15 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規かつ選択的なｃｃｒ２拮抗薬
WO2017004537A1 (fr) 2015-07-02 2017-01-05 Centrexion Therapeutics Corporation Citrate de (4-((3r,4r)-3-méthoxytétrahydro-pyran-4-ylamino)pipéridin-1-yl)(5-méthyl-6-(((2r,6s)-(p-tolyl)tétrahydro-2h-pyran-2-yl)méthylamino)pyrimidin-4-yl)méthanone
AU2016417658B2 (en) * 2016-08-01 2023-09-14 NZP1027 Ltd Transportation apparatus
CA3134613A1 (fr) 2019-04-02 2020-10-08 Aligos Therapeutics, Inc. Composes ciblant prmt5

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3882145A (en) * 1972-12-22 1975-05-06 Ppg Industries Inc Halogenated N-substituted thiocarboxy maleimides
HU175454B (hu) * 1977-07-25 1980-08-28 Chinoin Gyogyszer Es Vegyeszet Sposob poluchenija novykh predel'nykh i chastichno predel'nykh n-acil-pirrol-2,5-dionov
DE4029054A1 (de) * 1990-09-13 1992-03-19 Bayer Ag N-acylpyrrolidin-derivate
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US6686353B1 (en) 1996-05-20 2004-02-03 Teijin Intellectual Property Center Limited Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists
US6166037A (en) * 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
PL192083B1 (pl) 1997-11-18 2006-08-31 Dupont Pharmaceuticals Res Lab Pochodne amin cyklicznych i ich zastosowanie
US6288083B1 (en) * 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6303593B1 (en) * 1999-03-02 2001-10-16 Merck & Co., Inc. 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
AU3389300A (en) * 1999-03-02 2000-09-21 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
WO2000069815A1 (fr) 1999-05-13 2000-11-23 Teijin Limited Derives d'amines cycliques ureido-substituees et leur utilisation en tant que medicament
ES2250132T3 (es) 1999-05-18 2006-04-16 Teijin Limited Remedios preventivos para enfermedades asociadas a quimioquinas.
AU5600100A (en) * 1999-06-11 2001-01-02 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
CN1192773C (zh) 1999-08-04 2005-03-16 帝人株式会社 环胺ccr3拮抗剂
US6362177B1 (en) * 2000-05-16 2002-03-26 Teijin Limited Cyclic amine derivatives and their use as drugs
JP4029960B2 (ja) * 2001-10-05 2008-01-09 独立行政法人理化学研究所 アブシジン酸生合成阻害剤
WO2003093231A2 (fr) 2002-04-29 2003-11-13 Merck & Co., Inc. Modulateurs de l'activite des recepteurs des chimiokines a base de tetrahydropyranyl cyclopentyl tetrahydroisoquinoline
CA2483752C (fr) 2002-04-29 2011-03-29 Merck & Co., Inc. Modulateurs tetrahydropyranyl cyclopentyl tetrahydropyridopyridine de l'activite des recepteurs de chimiokine
JO2479B1 (en) 2002-04-29 2009-01-20 ميرك شارب اند دوم ليمتد Rates for the activity of the chemokine receptor of tetrahydrobranyl cycloneptil tetrahydrobredo predine
AU2003284984B2 (en) 2002-10-30 2008-10-23 Merck Sharp & Dohme Corp. Gamma-aminoamide modulators of chemokine receptor activity
CA2503844A1 (fr) 2002-10-30 2004-05-21 Merck & Co., Inc. Modulateur piperidinyl-alpha-aminoamide de l'activite de recepteurs de la chimiokine
EP1558576A4 (fr) 2002-10-30 2008-04-16 Merck & Co Inc Composes de piperidinyl cyclopentyl aryl benzylamide modulateurs de l'activite du recepteur de chimiokine
EP1558599A4 (fr) 2002-10-30 2007-06-27 Merck & Co Inc Modulateurs d'heteroarylpiperidine de l'activite des recepteurs de la chimiokine
JP2006514003A (ja) 2002-10-30 2006-04-27 メルク　エンド　カムパニー　インコーポレーテッド ケモカイン受容体活性のテトラヒドロピラニルシクロペンチルベンジルアミド調節剤
PL376925A1 (pl) * 2002-11-27 2006-01-09 Incyte Corporation Pochodne 3-aminopirolidyny jako modulatory receptorów chemokiny
AU2004287416C1 (en) 2003-10-27 2010-09-09 Merck Sharp & Dohme Corp. CCR-2 antagonist salt
AR045875A1 (es) 2003-10-27 2005-11-16 Merck & Co Inc Procedimiento para la preparacion del antagonista ccr-2
CA2545644C (fr) * 2003-11-12 2011-11-01 Lg Life Sciences Ltd. Agonistes du recepteur de la melanocortine
CA2551869A1 (fr) 2004-01-02 2005-07-28 Merck & Co., Inc. Modulateurs d'amide cyclopentyle d'alkylamino, arylamino et sulfonamido de l'activite des recepteurs de la chimiokine
WO2005070133A2 (fr) 2004-01-20 2005-08-04 Merck & Co., Inc. Piperidines disubstituees en 2,6, modulatrices de l'activite du recepteur de la chemokine
JP2007519734A (ja) 2004-01-28 2007-07-19 メルク　エンド　カムパニー　インコーポレーテッド アミノシクロペンチルピリドピラジノン系ケモカイン受容体活性調節剤
EP1742919A4 (fr) 2004-04-26 2010-04-28 Merck Sharp & Dohme Modulateurs tetrahydropyranyle cyclopentyle de tetrahydroisoquinoline 1 substituee et 1,1-disubstituee de l'activite des recepteurs de chimiokine
PA8653301A1 (es) * 2004-11-22 2006-11-09 Incyte Corp Incyte Corp Sales de la n-[2-({(3r)-1-[trans-4-hidroxi-4-(6-metoxipiridin-3-il) ciclohexil)pirrolidin

Also Published As

Publication number Publication date
IS2956B (is) 2016-12-15
CN102344398A (zh) 2012-02-08
US7576089B2 (en) 2009-08-18
NZ547316A (en) 2011-01-28
BRPI0417605B1 (pt) 2020-05-12
HK1166321A1 (en) 2012-10-26
EP1696919A4 (fr) 2009-07-01
US20140155377A1 (en) 2014-06-05
KR20080052683A (ko) 2008-06-11
WO2005060665A8 (fr) 2006-05-04
GEP20084505B (en) 2008-10-10
ZA200604875B (en) 2007-11-28
CA2550596C (fr) 2011-03-15
OA13338A (en) 2007-04-13
US8697870B2 (en) 2014-04-15
NO20063255L (no) 2006-09-14
AP2439A (en) 2012-08-31
JP4740151B2 (ja) 2011-08-03
EA013631B1 (ru) 2010-06-30
MXPA06007000A (es) 2006-08-31
NI200600136A (es) 2008-04-24
CA2550596A1 (fr) 2005-07-07
US20150231114A1 (en) 2015-08-20
EA200600991A1 (ru) 2006-10-27
BRPI0417605A (pt) 2007-03-27
KR100859027B1 (ko) 2008-09-17
BRPI0417605B8 (pt) 2021-05-25
NO336486B1 (no) 2015-09-07
DK1696919T3 (da) 2013-12-09
WO2005060665A2 (fr) 2005-07-07
EP1696919A2 (fr) 2006-09-06
US20170050942A1 (en) 2017-02-23
AP2006003629A0 (en) 2006-06-30
CR8455A (es) 2007-03-02
AU2004305079A1 (en) 2005-07-07
US20050192302A1 (en) 2005-09-01
US20090286792A1 (en) 2009-11-19
CN1893945A (zh) 2007-01-10
IL175953A0 (en) 2006-10-05
ES2439894T3 (es) 2014-01-27
JP2007514751A (ja) 2007-06-07
KR20070008536A (ko) 2007-01-17
UA82917C2 (en) 2008-05-26
EP1696919B1 (fr) 2013-10-02
AU2004305079B2 (en) 2011-05-12
WO2005060665A3 (fr) 2005-12-15
IL175953A (en) 2015-09-24
CN102344398B (zh) 2015-02-25
IS8466A (is) 2006-05-15
TNSN06188A1 (fr) 2007-11-15
ECSP066615A (es) 2006-10-25

Similar Documents

Publication Publication Date Title
PT1444215E (pt) Derivados de 1,2,4-triadiazolio como moduladores do receptor de melanocortina
AP2439A (en) 3-Cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
EP1829877A4 (fr) Dérivés bicycliques de pyrrole
NO20051042L (no) Pyrimidylsulfonamidderivater som kemokinreseptormodulatorer
EP1656138A4 (fr) Derives de cycloalkyamine substitues en tant que modulateurs de l'activite du recepteur de la chimiokine
DK1684731T3 (da) Filmdannende stivelsesholdig sammensætning
MA28347A1 (fr) Dérivés de quinoléine substitués
DK1756096T3 (da) Indolylderivater som lever-X-receptormodulatorer
AU2003259482A1 (en) N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators
AU2002353403A1 (en) Oxo or oxy-pyridine compounds as 5-ht4 receptor modulators
IL181241A0 (en) Pyrimidine sulphonamide derivatives as chemokine receptor modulators
EP1746141A4 (fr) Composition d' epaississement
DK1924561T3 (da) 6-arylalkylamino-2,3,4,5-tetrahydro-1h-benzo[d]azepiner as 5-ht2c-receptor agonister
EP1695761A4 (fr) Composition catalytique
AP2314A (en) 3- 4-heteroarylcyclohexylamino cyclopentanecarboxamides as modulators of chemokine receptors.
DE602004014772D1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
IL172760A0 (en) Pyrrole-2,5-dithione derivatives as liver x receptor modulators
IL182811A0 (en) Novel dicarboxamide derivatives
EP1751115A4 (fr) Modulateurs de theramuteine
IS8195A (is) Ásetnar pýrrólafleiður
NO20044337L (no) Faststoff-dispergeringspreparat
EP1697515A4 (fr) Conjugue adn-excipient
AU2003226396A1 (en) Imidazolidine compounds as chemokine receptor modulators
AU2003300711A1 (en) Substituted dihydropyrimidinone preparation using polyaniline salt catalyst
DE60230808D1 (de) Benzothiophene als adenosinrezeptormodulatoren